919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com
Settore/i:
Settore:
Impiegati a tempo pieno: 141
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1,36M | N/D | 1951 |
Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | 340,98k | N/D | 1967 |
Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 827,01k | N/D | 1964 |
Mr. Scott Samuels | Executive VP, Chief Legal Officer & Corporate Secretary | 485,32k | N/D | N/D |
Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Ms. Shannon Odam | Senior VP & Chief People Officer | N/D | N/D | 1975 |
Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 753,22k | N/D | 1964 |
Mr. Anil Kapur | Executive VP of Corporate Strategy & Chief Commercial Officer | 654,89k | N/D | 1970 |
Mr. Edward E. Koval | Executive VP & Chief Business Officer | N/D | N/D | 1962 |
Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | N/D | N/D | 1983 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
L'ISS Governance QualityScore di Geron Corporation al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 5; diritti degli azionisti: 9; retribuzione: 6.